Pixyl

Pixyl operates at the intersection of medical imaging software, neuroimaging biomarkers, and clinical decision support. Its differentiation is specialization: Pixyl.Neuro and related modules focus on quantitative MRI analysis for multiple sclerosis, stroke, brain atrophy, traumatic brain injury, and neurodegenerative conditions rather than broad radiology automation. The platform is designed for imaging CROs, neuroradiologists, neurologists, and clinical workflows, giving it a narrower but clinically specific proposition. The available peer information does not identify a validated list of direct competitors. Brainomix and Blackford are the closest named adjacent companies in Pixyl’s commercial network, although the available announcements describe them as partners rather than competitors. Gleamer is now the most important strategic reference point because its ownership can provide distribution, regulatory infrastructure, and cross-product integration. Pixyl’s €3.34 million in total recorded funding and estimated team size of 1–10 employees indicate a focused specialist rather than a scaled platform vendor. Its competitive position therefore depends on clinical validation, workflow integration, and the breadth of disease-specific biomarkers it can support.

Pixyl’s trajectory shows a long development cycle followed by strategic consolidation. Founded in 2015, the company raised a €600,000 seed round on Jul 1, 2016 and a €2.2 million venture round on Apr 29, 2021, bringing recorded funding to approximately $3.34 million. The 2021 round included Holnest, Bpifrance, and Elaia and appears to have supported the transition from research-oriented neuroimaging software toward a broader clinical and commercial product portfolio. Product coverage has expanded beyond a general Pixyl.Neuro platform to disease- and use-case-specific tools including Pixyl.Neuro.MS, Pixyl.Neuro.BV, Pixyl.Neuro.TBI, Pixyl Stroke Analysis, and the PRIMUS Platform. Partnerships with Brainomix in 2022 and Blackford in 2024 marked distribution and workflow-integration inflection points. Gleamer’s acquisition announcement on Mar 10, 2025 is the clearest structural milestone, potentially giving Pixyl access to a larger medical-imaging ecosystem. Current hiring for customer success in Southern Europe suggests ongoing implementation activity, while the small disclosed team indicates that scaling commercial execution remains an important challenge.